MedeliX
Start asking

atogepant

Aquipta · ATC code N02CD07

Key facts
Active substance
atogepant
Drug class
Antimigraine
ATC code
N02CD07
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
AQUIPTA 10 mg tablets / AQUIPTA 60 mg tablets
Marketing authorisation holder
AbbVie Deutschland GmbH & Co. KG
Information as of
2026-10-27

Key facts

Atogepant is an oral CGRP receptor antagonist (gepant, Aquipta). It is used for the acute treatment and prophylaxis of migraine in adults.

What it is used for

  • Acute treatment of migraine with or without aura in adults
  • Prophylaxis of migraine in adults with at least 4 migraine days per month

Dosing

  • Acute treatment: 60 mg as needed
  • Prophylaxis: 60 mg once daily
  • Maximum 60 mg per day; with or without meals, tablets swallowed whole
  • With strong CYP3A4 or OATP inhibitors: 10 mg once daily
  • Severe renal impairment and end-stage renal disease: 10 mg once daily, preferably after dialysis
  • Severe hepatic impairment: avoid

Contraindications

  • Hypersensitivity to the active substance or any of the excipients

Important warnings

  • Serious hypersensitivity reactions including anaphylaxis, mostly within 24 hours, sometimes days later; discontinue if they occur
  • Not recommended in severe hepatic impairment
  • The 60 mg tablet contains 31.5 mg sodium

Side effects

  • Prophylaxis: nausea (9%), constipation (8%), fatigue/somnolence (5%)
  • Acute treatment: nausea (1.3%)
  • Mostly mild or moderate

Interactions

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir) significantly increase atogepant exposure
  • OATP inhibitors (e.g., rifampicin, ciclosporin, ritonavir) significantly increase exposure
  • Weak or moderate CYP3A4 inhibitors: no clinically significant change expected

Pregnancy and breastfeeding

  • Not recommended during pregnancy and in women of childbearing potential not using contraception
  • Breast-feeding: minimal transfer into milk; benefits and risks are weighed

Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

Package leaflet for patients →

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • AquiptaAbbVie Deutschland GmbH & Co. KG · EMEA/H/C/005871

Source: European Medicines Agency (EMA), product information

Turkey

  • AquiptaABBVİE TIBBİ İLAÇLAR SAN. VE TİC. LTD. ŞTİ. · 5 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 3 more European countries
Iceland
Aquipta
Liechtenstein
Aquipta
Norway
Aquipta

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Aquipta – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/aquipta-epar-product-information_en.pdf
  2. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  3. Wikidata (CC0): ATC N02CD.

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.